GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zenith Capital Corporation (TSXV:ZENI.P) » Definitions » EV-to-FCF

Zenith Capital (TSXV:ZENI.P) EV-to-FCF : -1.05 (As of May. 29, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Zenith Capital EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Zenith Capital's Enterprise Value is C$20.15 Mil. Zenith Capital's Free Cash Flow for the trailing twelve months (TTM) ended in Jan. 2024 was C$-19.24 Mil. Therefore, Zenith Capital's EV-to-FCF for today is -1.05.

The historical rank and industry rank for Zenith Capital's EV-to-FCF or its related term are showing as below:

TSXV:ZENI.P' s EV-to-FCF Range Over the Past 10 Years
Min: -6.4   Med: 0   Max: 0
Current: -1.05

TSXV:ZENI.P's EV-to-FCF is not ranked
in the Biotechnology industry.
Industry Median: 8.835 vs TSXV:ZENI.P: -1.05

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-29), Zenith Capital's stock price is C$0.105. Zenith Capital's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jan. 2024 was C$-0.147. Therefore, Zenith Capital's PE Ratio for today is At Loss.


Zenith Capital EV-to-FCF Historical Data

The historical data trend for Zenith Capital's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zenith Capital EV-to-FCF Chart

Zenith Capital Annual Data
Trend Apr18 Apr19 Apr20 Apr21 Apr22 Apr23
EV-to-FCF
Get a 7-Day Free Trial - -5.62 -3.60 -18.43 -1.72

Zenith Capital Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.54 -1.72 -1.43 -1.44 -1.43

Competitive Comparison of Zenith Capital's EV-to-FCF

For the Biotechnology subindustry, Zenith Capital's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zenith Capital's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zenith Capital's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Zenith Capital's EV-to-FCF falls into.



Zenith Capital EV-to-FCF Calculation

Zenith Capital's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=20.145/-19.241
=-1.05

Zenith Capital's current Enterprise Value is C$20.15 Mil.
Zenith Capital's Free Cash Flow for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-19.24 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Zenith Capital  (TSXV:ZENI.P) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Zenith Capital's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.105/-0.147
=At Loss

Zenith Capital's share price for today is C$0.105.
Zenith Capital's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.147.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Zenith Capital EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Zenith Capital's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Zenith Capital (TSXV:ZENI.P) Business Description

Traded in Other Exchanges
N/A
Address
2475 Queens Avenue, West Vancouver, BC, CAN, V7V 2Y9
Zenith Capital Corporation is a clinical-stage biotechnology company focused on the discovery and development of novel therapeutics for the treatment of cancer and other disorders with significant unmet medical needs. The company is developing various novel combinations of BET inhibitors with other targeted agents. The lead compound, ZEN-3694, is in clinical development for mCRPC in combination with androgen receptor inhibitor, XTANDI, with Astellas and Newsoara as collaborators; triple-negative breast cancer in combination with the PARP inhibitor TALZENNA with Pfizer as a collaborator; androgen receptor independent mCRPC in combination with immune checkpoint inhibitor KEYTRUDA and XTANDI with University of California, San Francisco as a collaborator.

Zenith Capital (TSXV:ZENI.P) Headlines

No Headlines